纳洛酮对于老年慢性阻塞性肺疾病并发呼吸衰竭的临床疗效及安全性观察与分析

Observation and analysis of clinical efficacy and safety of naloxone in the treatment of senile chronic obstructive pulmonary disease complicated with respiratory failure

目的:研究纳洛酮治疗老年慢性阻塞性肺疾病(COPD)并发呼吸衰竭的效果。方法:收治COPD患者107例,将其分成治疗组与对照组。两组均实施持续低流量吸氧、止咳、祛痰、平喘、抗感染、呼吸训练等治疗,观察组在此基础上采用纳洛酮治疗。结果:随访期间,治疗组与对照组比较,复发次数和复发率明显降低(P<0.01);治疗组的FVC、FEV_1、FEV_1/FVC、MVV均明显升高,RV、RV/TLC均明显降低;治疗组的血清IgG、IgA、IgM水平及CD3^+、CD4^+、CD4^+/CD8^+水平均明显升高,与治疗前和对照组比较,差异均具有统计学意义(P<0.05)。结论:应用纳洛酮可改善老年COPD伴呼吸衰竭患者的治疗效果。

Objective:To study the efficacy of naloxone in the treatment of elderly chronic obstructive pulmonary disease(COPD)complicated with respiratory failure.Methods:107patients with COPD were selected.They were divided into the treatment groupand the control group.The two groups were treated with continuous low flow oxygen inhalation,cough relief,expectorant,antiasthmatic,anti infection,respiratory training,and so on.The observation group was treated with naloxone on this basis.Results:During the follow-up period,the recurrence number and recurrence rate of the treatment group were significantly lower than thoseof the control group(P<0.01).The levels of FVC,FEV1,FEV1/FVC and MVV in the treatment group were significantly increased,and the RV and RV/TLC levels decreased significantly.The levels of serum immunoglobulin IgG,IgA,IgM,and the levels of CD3+,CD4+,CD4+/CD8+in the treatment group were significantly increased.Compared with before treatment and the control group,thedifferences were statistically significant(P<0.05).Conclusion:Naloxone can improve the therapeutic effect of COPD inmiddle-aged patients with respiratory failure.